Citation profile for Martina Garau

Martina Garau : Citation Profile

Office of Health Economics

H index

i10 index

Citations

RESEARCH PRODUCTION:

Articles

Papers

Books

RESEARCH ACTIVITY:

   50 years (1970 - 2020). See details.
   Cites by year: 1
   Journals where Martina Garau has often published
   Relations with other researchers
   Recent citing documents: 4.    Total self citations: 6 (8.45 %)

MORE DETAILS IN:

EconPapers

ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pga966
   Updated: 2024-01-16    RAS profile: 2020-07-23
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers

Works with:

Zhang, Kyann (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Martina Garau.

Is cited by:

Shah, Koonal (4)

Towse, Adrian (4)

Devlin, Nancy (2)

Berdud, Mikel (1)

Cubi-Molla, Patricia (1)

Brazier, John (1)

LEVAGGI, ROSELLA (1)

Mott, David (1)

Sanchez Martinez, Fernando Ignacio (1)

pinto-prades, jose-luis (1)

Hampson, Grace (1)

Cites to:

Devlin, Nancy (10)

Towse, Adrian (9)

Parkin, David (4)

Danzon, Patricia (4)

Shah, Koonal (3)

Docteur, Elizabeth (3)

Andreoni, James (3)

Brazier, John (3)

Tsuchiya, Aki (3)

Rice, Nigel (3)

Feng, Yan (2)

Main data

Where Martina Garau has published?

Working Papers Series with more than one paper published	# docs
Briefing / Office of Health Economics	4

Recent works citing Martina Garau (2024 and 2023)

Year	Title of citing document
2023	Barriers and facilitators to implementing priority setting and resource allocation tools in hospital decisions: A systematic review. (2023). Cutler, Henry ; Gu, Yuanyuan ; Seil, Elizabeth ; Bilgrami, Anam ; Jeet, Varinder ; Ahumada-Canale, Antonio. In: Social Science & Medicine. RePEc:eee:socmed:v:322:y:2023:i:c:s0277953623001478. Full description at Econpapers \|\| Download paper
2023	How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts. (2023). Joos, Guy ; Welte, Tobias ; Angus, Colin ; Franklin, Matthew. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:21:y:2023:i:4:d:10.1007_s40258-023-00802-y. Full description at Econpapers \|\| Download paper
2023	Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments. (2023). Drummond, Michael ; Facey, Karen ; Whittal, Amanda ; Upadhyaya, Sheela ; Meregaglia, Michela ; Morel, Thomas ; Lloyd, Andrew J ; Nicod, Elena. In: The Patient: Patient-Centered Outcomes Research. RePEc:spr:patien:v:16:y:2023:i:1:d:10.1007_s40271-022-00598-4. Full description at Econpapers \|\| Download paper
2023	Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease. (2023). Rutherford, Carolyn ; Kirchmann, Matt ; Zibelnik, Natasa ; Wayi-Wayi, Grace ; Ademi, Zanfina ; Abrams, Keith R ; Shupo, Francis ; Makarounas-Kirchmann, Kelly. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:7:y:2023:i:5:d:10.1007_s41669-023-00426-x. Full description at Econpapers \|\| Download paper

Works by Martina Garau:

Year	Title	Type	Cited
2009	Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries In: Briefing. [Full Text][Citation analysis]	paper	7
1970	Estimating Pharmaceutical Companies Value to the Nation: Case Study of the British Pharma Group In: Briefing. [Citation analysis]	paper	0
2018	Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward In: Briefing. [Full Text][Citation analysis]	paper	4
2019	How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefing. [Full Text][Citation analysis]	paper	3
2011	Exploring the Interdependency between Public and Charitable Medical Research In: Consulting Report. [Full Text][Citation analysis]	paper	0
2010	Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society In: Consulting Report. [Full Text][Citation analysis]	paper	0
2009	Assessment and Appraisal of Oncology Medicines: NICEs Approach and International HTA Experience In: Consulting Report. [Full Text][Citation analysis]	paper	0
2006	Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions In: Consulting Report. [Full Text][Citation analysis]	paper	0
2014	Obstructive Sleep Apnoea: Health Economics Report In: Consulting Report. [Full Text][Citation analysis]	paper	2
2016	Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Report. [Full Text][Citation analysis]	paper	0
2017	Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study In: Consulting Report. [Full Text][Citation analysis]	paper	0
2017	Policy Options for Formulary Development in Middle-income Countries In: Consulting Report. [Full Text][Citation analysis]	paper	0
2017	Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries In: Consulting Report. [Full Text][Citation analysis]	paper	1
2018	Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence In: Consulting Report. [Full Text][Citation analysis]	paper	2
2019	Unrelieved Pain in Palliative Care in England In: Consulting Report. [Full Text][Citation analysis]	paper	0
2020	Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making? In: Consulting Report. [Full Text][Citation analysis]	paper	3
2020	International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making In: Consulting Report. [Full Text][Citation analysis]	paper	4
2007	European Medicines Pricing and Reimbursement: Now and the Future In: Monograph. [Full Text][Citation analysis]	book	0
2011	Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Paper. [Full Text][Citation analysis]	paper	2
2013	Exploring the link between health and wealth in decision making In: Research Paper. [Full Text][Citation analysis]	paper	0
2013	Multi-Criteria Decision Analysis to Value Orphan Medicines In: Research Paper. [Full Text][Citation analysis]	paper	14
2012	Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? In: Research Paper. [Full Text][Citation analysis]	paper	5
2010	Using QALYs in Cancer: Review of the Methodological Limitations In: Research Paper. [Full Text][Citation analysis]	paper	12
2014	Exploring the Interdependencies of Research Funders in the UK In: Research Paper. [Full Text][Citation analysis]	paper	2
2016	Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Paper. [Full Text][Citation analysis]	paper	0
2018	R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C In: Research Paper. [Full Text][Citation analysis]	paper	3
2018	Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: PharmacoEconomics - Open. [Full Text][Citation analysis]	article	1

	book	article	paper
1980	0	0	0
1981	0	0	0
1982	0	0	0
1983	0	0	0
1984	0	0	0
1985	0	0	0
1986	0	0	0
1987	0	0	0
1988	0	0	0
1989	0	0	0
1990	0	0	0
1991	0	0	0
1992	0	0	0
1993	0	0	0
1994	0	0	0
1995	0	0	0
1996	0	0	0
1997	0	0	0
1998	0	0	0
1999	0	0	0
2000	0	0	0
2001	0	0	0
2002	0	0	0
2003	0	0	0
2004	0	0	0
2005	0	0	0
2006	0	0	1
2007	1	0	0
2008	0	0	0
2009	0	0	2
2010	0	0	2
2011	0	0	2
2012	0	0	1
2013	0	0	2
2014	0	0	2
2015	0	0	0
2016	0	0	2
2017	0	0	3
2018	0	1	3
2019	0	0	2
2020	0	0	2